10x Genomics (TXG) Shares Outstanding (Weighted Average) (2018 - 2026)

10x Genomics' Shares Outstanding (Weighted Average) history runs 9 years deep, the most recent figure standing at $128.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 4.64% year-over-year to $128.3 million; the TTM figure through Mar 2026 stood at $128.3 million (up 4.64% YoY), while the FY2025 annual figure was $124.7 million, up 3.57% from the prior year.
• Shares Outstanding (Weighted Average) came in at $128.3 million for Q1 2026 at 10x Genomics, up from $124.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $128.3 million in Q1 2026 to a low of $113.0 million in Q1 2022.
• A 5-year average of $119.2 million and a median of $119.4 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) grew 2.35% in 2023 and climbed 4.64% in 2026, its largest moves.
• 10x Genomics' Shares Outstanding (Weighted Average) stood at $113.9 million in 2022, then gained by 2.9% to $117.2 million in 2023, then increased by 2.81% to $120.5 million in 2024, then rose by 3.57% to $124.7 million in 2025, then climbed by 2.84% to $128.3 million in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $128.3 million, $124.7 million, and $125.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison